The body your patients keep covering up
There is a pattern showing up with increasing frequency in aesthetic medicine practices: a patient who has invested years in facial rejuvenation — fillers, biostimulators, skin boosters, neurotoxin — but whose neck and décolleté tell a different story. The chest was never protected. It was never treated. And now, at 50 or 55, it reveals everything the face has been trained to conceal.
This disconnect has become more clinically visible in recent years for a specific reason: GLP-1 receptor agonist therapy. Rapid weight loss associated with semaglutide and tirzepatide accelerates structural changes in the décolleté — laxity, crepey texture, collagen loss — in ways that parallel advanced photoaging but on a compressed timeline. Patients who have lost 30, 40, or 50 pounds are presenting with chest and neck changes that significantly outpace their facial appearance.
The protocol described here addresses this reality with a three-layer injectable approach calibrated specifically to the anatomical profile of this zone and to the biological mechanisms of its deterioration.
Neck and décolleté rejuvenation: why this zone responds differently to injectables
Treating the chest with the same clinical logic applied to the face is a common and consequential error. The tissue is structurally different in ways that matter.
Anatomical profile: The décolletage dermis is thinner than most facial zones, with significantly lower sebaceous gland density and far fewer pilosebaceous units. NCT05163353 — a prospective multicenter randomized trial evaluating diluted CaHA for décolleté rejuvenation — documents over 13 times fewer hair follicles in the chest versus the lateral forehead. 1 This difference directly affects product spread, safe injection depth, healing capacity, and overinjection risk. 1
Reduced sebaceous activity permanently impairs lipid barrier function and accelerates transepidermal water loss. Combined with cumulative UV exposure — most patients applied SPF daily to their faces but never to their chests — the result is advanced ECM degradation: fragmented collagen, disorganized elastin, diminished fibroblast synthetic output that predates comparable facial changes by years. 1 In peri- and post-menopausal patients, estrogen-driven collagen loss and skin thinning compound this further. 1
In practice: this is the zone that fails to respond to surface hydration and overreacts to volumizing strategies designed for facial tissue. The biological deficit here is structural, not cosmetic.
Mesotherapy for neck and décolleté rejuvenation: building the cellular foundation
What mesotherapy does in this protocol
Mesotherapy here is not a hydration treatment or a biostimulator. It is the intradermal delivery of a multi-ingredient formulation — vitamins, amino acids, minerals, coenzymes, and hyaluronic acid — with one preparatory objective: replenishing the cellular raw materials depleted tissue needs before any remodeling stimulus is introduced. Biostimulation applied to nutritionally depleted fibroblasts underperforms regardless of the agent used.
Clinical schedule
2–3 sessions, 2–3 weeks apart, administered intradermally across the full treatment field.
The strongest published clinical evidence for this zone belongs to NCTF 135HA . The HEBE2 study — a randomized, active-controlled, multicenter trial across 10 centers with 146 subjects — evaluated NCTF 135HA injections specifically across the face, neck, and décolleté. 2 At Day 75 and Day 120, NCTF 135HA significantly reduced wrinkles in all three areas and improved skin radiance scores versus the active cream control group. 2 It remains the only well-powered published RCT evaluating a mesotherapy product specifically on the neck and décolleté.
Product selection by dominant deficit:
- Photoaging and oxidative damage (dyspigmentation, compromised barrier, advanced texture change): Cytocare 532 — non-cross-linked HA with 20 amino acids and antioxidant co-factors formulated for photodamaged tissue.
- Depleted fibroblast synthetic capacity : Jalupro HMW — amino acid precursors for collagen synthesis (glycine, L-proline, L-leucine, L-lysine) with high molecular weight HA. Approved indications include neck, décolleté, and hands specifically. The amino acid substrate creates mechanistic continuity with Layer 03: the fibroblasts primed here are the same cells subsequently activated by biostimulation.
For the complete reference of injectable mesotherapy protocols for neck and décolleté , including concentration and session guidance, see the product range.
Skin Boosters for décolleté: hydration versus volumization — a clinical distinction
Skin Booster vs. dermal filler: why the distinction matters in this zone
A Skin Booster is a low or non-cross-linked hyaluronic acid injectable designed to restore ECM water-binding capacity at a tissue level. It does not volumize. The distinction from a dermal filler is categorical — different cross-linking, different rheology, different biological objective. Conflating the two in the décolleté is a clinical risk in thin, reactive tissue where overinjection consequences are magnified.
Clinical schedule
1–2 sessions, 4 weeks after the final Layer 01 session. Can be introduced as a split-protocol alongside Layer 01 in appropriate patient profiles.
A well-hydrated dermis before biostimulation is not optional — it is functional. ECM hydration creates the tissue conditions in which Layer 03 products act more efficiently and produce more durable results. Biostimulation delivered into dehydrated dermis structurally underperforms.
Product selection by patient profile:
- Significant hydration deficit, mature or photodamaged skin, pronounced crepey texture: Ejal 40 — 40 mg/ml non-cross-linked high molecular weight HA. High concentration for rapid dermal water restoration.
- Thin, reactive tissue; priority on uniform distribution: Refine+ Ultra Soft — 20 mg/ml cross-linked HA with low rheological profile. Engineered specifically for thin, reactive anatomy — not a performance compromise.
The full selection of Skin Boosters for décolleté hydration is available by concentration and molecular weight profile.
Biostimulators for neck and décolleté: driving structural collagen and elastin remodeling
Biostimulator vs. Skin Booster: different mechanisms, different timelines
A biostimulator stimulates endogenous collagen and/or elastin production through fibroblast activation or scaffold-mediated tissue response. Results are progressive: peak collagen remodeling typically occurs 3–6 months from the first session. This is mechanistically distinct from the immediate hydration a Skin Booster provides. Treating them as interchangeable is an indication error.
Clinical schedule
Begin minimum 2–4 weeks after the final Layer 01 session. Two sessions, 4 weeks apart.
Clinical options by mechanism:
- Sunekos 200 — Low molecular weight HA + patented six amino acid formula (glycine, L-proline, L-hydroxyproline, L-leucine, L-lysine, L-valine). Simultaneously induces collagen and elastin synthesis. 3 Elastin induction is clinically critical in this zone: elastin degradation drives the laxity and crepey texture that characterize décolleté photoaging and is underaddressed by most biostimulators. Mechanistically continuous with Jalupro HMW Layer 01 priming.
- Radiesse (+) 1.5ml hyperdiluted — CaHA microspheres as biostimulatory scaffold: as the calcium hydroxylapatite degrades, it triggers fibroblast proliferation, neocollagenesis, neoelastinogenesis, and angiogenesis. 4,5 Mazzuco et al. prospective trial — 20 subjects, 1:2 dilution, 12-month follow-up — achieved statistically significant Merz Décolleté Scale improvements from a single treatment, maintained at Day 360. 4 Sunekos 200 and Radiesse (+) are complementary, not alternatives: different induction pathways in the same tissue produce additive structural outcomes. 5
- StiCol Volume — PLLA + HA hybrid. Indicated when structural deficit exceeds what a standard biostimulation course can address, or when visit frequency must be minimized. Particularly relevant for GLP-1 patients with rapid-onset structural loss where long-term scaffold support is the clinical priority. PLLA drives sustained collagen neogenesis over months, 6 with published evidence specific to décolleté application by Wilkerson and Goldberg. 7 Duration: up to 24 months.
The complete reference of biostimulators for décolleté structural remodeling , including mechanism comparisons and session guidance, is available in the product range.
Neck and décolleté protocol: matching treatment to the clinical presentation
| Presentation | Protocol | Products |
|---|---|---|
| Mild–moderate photodamage, early laxity | Layers 01 + 02 | NCTF 135HA or Jalupro HMW + Ejal 40 or Refine+ Ultra Soft |
| Visible laxity, structural thinning, collagen deficit | Layers 01 + 02 + 03 | Above + Sunekos 200 or hyperdiluted Radiesse (+) |
| Advanced structural deficit, GLP-1 rapid loss, or low visit frequency | Layers 01 + 02 + 03 (StiCol) | Above with StiCol Volume as Layer 03 |
Every combination is available as a complete product selection on Fräya Med Supply. View neck & décolleté protocol products .
In US practice, the three profiles presenting most frequently in this zone are: cumulative photoaging from years of unprotected sun exposure, peri- and post-menopausal skin changes, and — with rapidly growing frequency — accelerated structural loss associated with GLP-1 receptor agonist therapy. In all three, the full three-layer protocol is typically the correct approach.
When to start: seasonal and clinical timing for the décolleté protocol
Biostimulation results are not immediate — they require 3–6 months to reach peak collagen remodeling output. Initiating the protocol now aligns that peak with the summer exposure window. For GLP-1 patients experiencing active body composition changes, early initiation is particularly relevant: structural support begun before peak weight loss stabilization produces better long-term outcomes.
| Timing | Layer | Sessions |
|---|---|---|
| May–June | Layer 01 — Mesotherapy foundation | 2–3 sessions, 2–3 weeks apart |
| June | Layer 02 — Skin Booster | 1–2 sessions, 4 weeks after final Layer 01 |
| June–July | Layer 03 — Biostimulation | 2 sessions, 4 weeks apart |
| July–September | Peak improvement window | — |
Nefertiti Lift: the neuromodulator complement to the injectable protocol
For patients already receiving this injectable protocol, the logical BTX-A addition is the Nefertiti Lift, first described by Levy in Journal of Cosmetic and Laser Therapy in 2007. 8 The technique delivers botulinum toxin type A along the inferior mandible and into the platysmal bands, softening vertical neck bands and restoring mandibular definition without surgery. 8
The tissue quality improvements produced by Layers 01–03 create a better-hydrated, more structurally intact dermal environment. Clinical observation suggests this extends the visible duration of the toxin effect. The injectable protocol and the BTX-A work reinforce each other.
■ Clinical Summary
- The décolleté has over 13× fewer pilosebaceous units than the lateral forehead 1 and greater accumulated UV damage without photoprotection. Protocol logic must be calibrated to this anatomy, not adapted from facial protocols.
- A three-layer sequence addresses cellular nutrition, dermal hydration, and structural remodeling as distinct biological objectives in the correct order. Compressing the sequence compromises the compounding outcome.
- NCTF 135HA is the only mesotherapy product with published RCT data specifically on the neck and décolleté (HEBE2, 2023). 2 Hyperdiluted Radiesse (+) has prospective clinical trial data specific to chest rejuvenation (PMID 33938688). 4
- GLP-1-related rapid weight loss accelerates structural décolleté changes on a compressed timeline. The full three-layer protocol — with PLLA-based options for long-term scaffold support — is typically indicated for this profile.
- Two clinical entry points: Layers 01 + 02 for mild-to-moderate presentations; full three-layer remodeling for visible laxity, structural thinning, advanced collagen deficit, or GLP-1-related changes.
References
- NCT05163353. Evaluation of the Effectiveness and Safety of Diluted RADIESSE® in the Treatment of Décolleté Wrinkles. ClinicalTrials.gov. clinicaltrials.gov/study/NCT05163353
- Fanian F et al. HEBE2 study. J Dermatol Treat. 2023;34(1):2216323. DOI: 10.1080/09546634.2023.2216323
- Sacchi P, Rauso R. Clin Dermatol J. 2018;3(2):000152.
- Mazzuco R et al. J Drugs Dermatol. 2021;20(5). PMID: 33938688. DOI: 10.36849/JDD.5680
- Goldie K et al. Dermatol Surg. 2018;44(Suppl 1):S32–S41. PMID: 30358631.
- Vleggaar D. Plast Reconstr Surg. 2006;118(3 Suppl):46S–54S. PMID: 16936520.
- Wilkerson EC, Goldberg DJ. J Cosmet Dermatol. 2018;17(4):606–610. DOI: 10.1111/jocd.12447
- Levy PM. J Cosmet Laser Ther. 2007;9(4):249–252. PMID: 18236245.
